Azenta, Inc. (AZTA) · Aug 4, 2026 · Company update

Revenue and adjusted EPS beat decisively; organic outlook edges higher.

Revenue and adjusted EPS beat decisively; organic outlook edges higher.

The quarter cleared a low bar by a wide margin. Published consensus was about $149.3 million of revenue and $0.11 of adjusted EPS; Azenta delivered $161.2 million and $0.16, a roughly $11.9 million revenue beat and $0.05 EPS beat. Both operating segments grew at double digits, rather than the prior quarter's weak backdrop carrying through. (Financial Highlights; Non-GAAP EPS reconciliation; Organic Revenue table)

MetricQ3 FY2026 actualQ3 FY2025Prior quarterExpectation / outlook change
Continuing-operations revenue$161.2M$143.9M$144.8MPublished consensus: ~$149.3M (Income Statement)
Organic revenue growth9%——FY2026 outlook raised to flat to +1%, from -2% to +1% (Organic Revenue table; Outlook)
Non-GAAP diluted EPS, continuing operations$0.16$0.17$(0.04)Published consensus: ~$0.11 (Non-GAAP EPS reconciliation)
Adjusted EBITDA$18.5M$17.4M$7.8MMargin: 11.4% vs. 12.1% a year ago (Adjusted EBITDA reconciliation)
Adjusted gross margin46.2%47.6%44.3%Down 140 bps year over year (Adjusted Gross Profit table)

The guidance change is modestly better, not a wholesale reset. Full-year revenue was narrowed to $613–$618 million from $603–$621 million: the midpoint rises by $3.5 million, while the bigger signal is the organic-growth floor moving from a 2% decline to flat. That validates the quarter's rebound, but the company still expects low-single-digit sequential organic decline in Q4—so management is not declaring demand fully repaired. (Outlook)

Growth improved across both businesses, which makes the beat more credible. Sample Management revenue rose 14% year over year, including 9% organic growth, while Multiomics rose 10%, including 8% organically. Still, some weak pockets remain: Automated Stores and Sanger Sequencing declined, meaning the recovery is broadening but not yet uniform. (Segment revenue and organic-growth discussion)

Margins remain the limiting factor on the turnaround. Adjusted EBITDA rose 6% year over year, but adjusted gross margin fell 140 basis points because of lower-volume fixed-cost absorption and Automated Stores quality-remediation/rework costs. The quarter therefore beat expectations on sales and adjusted profit, while showing that conversion of that growth into sustainably better margins remains unfinished. (Adjusted EBITDA reconciliation; Adjusted Gross Profit table)

The headline GAAP profit should not be mistaken for core profitability. Total diluted EPS was $0.05, but continuing operations lost $0.03 per share; the positive total came from $0.09 per share in discontinued operations related to B Medical Systems, which was sold on July 1. The cleaner operating read is the $0.16 adjusted EPS from continuing operations. (Income Statement; Financial Highlights; Non-GAAP EPS reconciliation)

Balance-sheet capacity remains ample, though cash generation weakened. Cash plus marketable securities were about $522 million at June 30, while the company used $50.0 million for repurchases and generated $35.8 million of operating cash flow in the first nine months, down from $70.0 million a year earlier. That does not undermine the earnings beat, but it keeps attention on whether the improving revenue base translates into stronger cash conversion. (Balance Sheet; Cash Flow Statement)

Original filing on SEC EDGAR

More Azenta, Inc. news

Revenue and adjusted EPS beat decisively; organic outlook edges higher. | AZTA Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.